Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research InstituteSBA Member News, 30.09.2014
Mymetics Corporation (OTCQB: MYMX), a pioneer in
the research and development of virosome-based vaccines to prevent transmission of human
infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine
candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.